Floatz logo

Tagitanlimab

PD-L1 Positive

Tianjin Medical University Cancer Institute and Hospitalmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the PD-L1 Positive cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Gilead Sciences
Phase 3B
Pembrolizumab
Gilead Sciences
Phase 3B
Epirubicin
Gilead Sciences
Phase 3B
Carboplatin
Gilead Sciences
Phase 3B
Sacituzumab Tirumotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 2CCC

View all 12 →

Same molecule, other indications

Tagitanlimab is also rated in:

prostate adenocarcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
Prostate Adenocarcinoma With Neuroendocrine DifferentiationDormant
CCC
Indicative ·
53 / 100
View asset →
castration-resistant prostate carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →